spacer
home > ebr > spring 2019 > accessing difficult-to- synthesise metabolites in drug development programmes
PUBLICATIONS
European Biopharmaceutical Review

Accessing Difficult-to- Synthesise Metabolites in Drug Development Programmes

Access to major and/or disproportionate metabolites as part of drug development programmes is critical to ensure adherence to regulatory guidelines issued by the EMA and FDA, as well as to comply with internal safety standards within pharmaceutical companies themselves (1-2).

Identification and characterisation of metabolites ensures not only rigorous safety evaluation of significant metabolites, but can also expand patent coverage and reveal superior potency, reduced side effects, or improved physical properties compared to the parent drug.

Multiple options are available for making metabolites through both chemical and biological routes, as discussed by scientists at Abbvie (3) and summarised in Figure 1.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Julia Shanu-Wilson has over 25 years’ experience in the biotechnology and drug discovery industries. Following a BSc and PhD in microbial biochemistry at Imperial College London, UK, Julia worked in the biotech and pharma industries holding research leadership positions with Xenova, Cubist Pharmaceuticals, and TMO. She joined Hypha Discovery in 2013 and is on the management team, leading scientific communications for the company.
spacer
Julia Shanu-Wilson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gerresheimer manufactures sustainable primary plastic packaging

Düsseldorf, January 14, 2020. Consumers are placing great importance on eco-friendly plastic packaging products, specifically – and increasingly – on sustainable packaging solutions that can be disposed of in an environmentally friendly way. At Gerresheimer, therefore, innovation and environmental protection go hand in hand. A pioneer in the quest for greater sustainability, Gerresheimer offers an extensive standard range of plastic packaging and devices customized solutions made from PET, R-PET, and BIO-PET plastics.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement